The National Cancer Institute is offering the Immuno-Oncology Translation Network (IOTN) grant in association with the Beau Biden Cancer Moonshot Initiative. The grant aims to advance translational research on immune mechanisms in tumor development and progression, focusing on immunopreventive and immunotherapeutic strategies. Projects should be pre-clinical with the potential for rapid translation into clinical applications. Applicants must apply for both UG3 and UH3 phases in a single application, with UG3 supporting immune target identification and validation. Transition to the UH3 Implementation Phase requires meeting UH2 milestones. The UH3 phase focuses on the development and preclinical testing of interventions. Closing date for applications is February 11, 2019.
Opportunity ID: 310037
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-19-012 |
| Funding Opportunity Title: | Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (UG3/UH3) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Environment Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.113 — Environmental Health |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Oct 31, 2018 |
| Last Updated Date: | Oct 31, 2018 |
| Original Closing Date for Applications: | Feb 11, 2019 |
| Current Closing Date for Applications: | Feb 11, 2019 |
| Archive Date: | Mar 19, 2019 |
| Estimated Total Program Funding: | $2,000,000 |
| Award Ceiling: | $500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Special district governments Independent school districts Small businesses Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) County governments For profit organizations other than small businesses City or township governments Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to support UG3/UH3 phased award Projects as part of the expanded Immuno-Oncology Translational Network (IOTN). The IOTN will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating translational research of innate and adaptive immune mechanisms that contribute to tumor initiation and progression and evaluating new or improved immunopreventive and immunotherapeutic strategies (including combinations with standard or other therapies). Studies should be largely pre-clinical involving clinically-relevant models and endpoints, and have the potential for rapid translation into early-phase clinical applications. Applicants responding to this FOA must apply for both the UG3 and UH3 phases together in a single application. Exploratory studies aimed at immune target identification and validation will be supported under UG3. Achievement of the UH2 milestones will be necessary for transition to the UH3 Implementation Phase. UH3 phase may be awarded after administrative review of the UH2 milestones. Provided these milestones are achieved, UH3 phase may continue with development and preclinical testing of specific interventions. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-19-012.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-E | FORMS-E | PKG00246003 | Jan 11, 2019 | Feb 11, 2019 | View |
Package 1
Mandatory forms
310037 RR_SF424_2_0-2.0.pdf
310037 PHS398_CoverPageSupplement_4_0-4.0.pdf
310037 RR_OtherProjectInfo_1_4-1.4.pdf
310037 PerformanceSite_2_0-2.0.pdf
310037 RR_KeyPersonExpanded_2_0-2.0.pdf
310037 RR_Budget_1_4-1.4.pdf
310037 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
310037 RR_SubawardBudget30_1_4-1.4.pdf
310037 PHS_AssignmentRequestForm_2_0-2.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
